Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
NCT00626197 · Genentech, Inc. · PHASE3 · terminated · last registry update 2020-12-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.” | – | Registry record, Genentech, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-01Phase 3 first posted: Neurocrine UK Limited, Chronocort + Cortef (NCT05063994)
- 2021-06-03Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT01856192)
- 2021-04-13Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2021-03-16Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04799275)
- 2021-02-18Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04759586)
- 2020-12-23Results posted on the registry: OHSU Knight Cancer Institute, Cabazitaxel + Enzalutamide (NCT02522715)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
- 2020-07-14Phase 3 first posted: Cristcot HCA LLC, Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator + Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator (NCT04469686)
- 2020-05-11Phase 3 first posted: University of Oxford, Lopinavir-Ritonavir + Corticosteroid (NCT04381936)
- 2020-04-24Phase 3 first posted: University Hospital, Tours, Prednisone + Hydrocortisone (NCT04359511)
- 2020-03-03Phase 3 first posted: Children's Oncology Group, Asparaginase Erwinia chrysanthemi + Cytarabine (NCT04293562)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision